BC Innovations | Mar 8, 2017
Distillery Therapeutics


INDICATION: Adjuvant Cell culture and mouse studies suggest a synthetic glycolipid adjuvant could help improve the efficacy of vaccines for infectious diseases with less toxicity than conventional adjuvants. In human monocytes and mouse monocyte-derived dendritic...
BC Innovations | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer S100 calcium binding protein A8 (S100A8; calgranulin A; MRP8); S100A9 (calgranulin B; MRP14) In vitro and mouse studies identified myeloid-derived suppressor cell (MDSC)-depleting peptides...
BC Innovations | May 9, 2013
Targets & Mechanisms

AD vaccine redux

Researchers at Harvard Medical School have teamed up with vaccine maker Mercia Pharma Inc. to design a next-generation Alzheimer's disease vaccine with an adjuvant that promotes a beneficial anti-inflammatory response that the team hopes will...
BC Week In Review | Feb 3, 2003
Company News

Elan other research news

Researchers published in the Proceedings of the National Academy of Sciences an analysis of different anti-beta-amyloid antibodies showing that antibodies that bind to the amino-terminal regions of beta-amyloid induced plaque clearance in a mouse model...
BC Week In Review | Feb 3, 1997
Clinical News

Cel-Sci preclinical data

CELI presented mouse data at the Conference on Retroviruses and Opportunistic Infections in Washington showing that a heteroconjugate of its HGP-30 AIDS vaccine works better than a previous version. The heteroconjugate consists of a segment,...
Items per page:
1 - 5 of 5